Breaking News Instant updates and real-time market news.

CVX

Chevron

$112.51

-0.91 (-0.80%)

09:05
01/14/19
01/14
09:05
01/14/19
09:05

Chevron downgraded to Hold on lower crude price assumptions at HSBC

As previously reported, HSBC analyst Gordon Gray downgraded Chevron to Hold from Buy and lowered his price target to $122 from $136 after lowering his base case Brent crude price assumption for 2019 to $64 per barrel. The scale of U.S. supply, and its responsiveness to any significant hike in price, will likely limit the price upside for crude, Gray tells investors. His downgrade of the stock is also predicated on the stock's recent rally to a five-year high versus the global sector, Gray noted. However, with free cash breakevens in levels in the low $50/barrel range, he thinks the outlook for most companies is "robust" with Brent trading near $60/barrel, Gray stated.

  • 01

    Feb

  • 10

    Feb

CVX Chevron
$112.51

-0.91 (-0.80%)

01/14/19
HSBC
01/14/19
DOWNGRADE
Target $122
HSBC
Hold
Chevron downgraded to Hold from Buy at HSBC
HSBC analyst Gordon Gray downgraded Chevron to Hold from Buy and lowered his price target to $122 from $136.
11/05/18
11/05/18
UPGRADE
Target $138

Outperform
Chevron upgraded to Outperform on continued execution at Credit Suisse
As previously reported, Credit Suisse analyst William Featherston upgraded Chevron to Outperform from Neutral, with a $138 price target, citing continued execution, free cash flow visibility and compelling valuation. The analyst believes the company continues to execute on its already superior growth outlook, which should translate into better than expected capital efficiencies into 2019 and sets up for continued robust free cash flow. He sees upside to 2019-2020 volume forecasts supported by strong Permian growth, driving an estimated about $10B-$11B per annum of surplus free cash flow generation, which should enable Chevron to sustain competitive dividend growth and expand the scope of its current share buyback program.
11/05/18
FBCO
11/05/18
UPGRADE
FBCO
Outperform
Chevron upgraded to Outperform from Neutral at Credit Suisse
10/22/18
SIMM
10/22/18
INITIATION
Target $139
SIMM
Overweight
Chevron assumed with an Overweight at Simmons
Simmons analyst Blake Fernandez assumed Chevron with an Overweight rating and a price target of $139 as part of his broader research note on Integrated Oils, suggesting that the industry stands to benefit from the current stage of the energy cycle. Fernandez adds that Chevron is his Top Idea given that it had the worst year-to-date equity performance in the peer group and expects the stock to "play catch-up". The analyst further points to the company's "ample Permian takeaway capacity" as alleviation of "industry bottlenecks next year could prompt fund rotation back into equities with leverage" to the region.

TODAY'S FREE FLY STORIES

AIG

AIG

$44.15

0.86 (1.99%)

07:27
01/22/19
01/22
07:27
01/22/19
07:27
Recommendations
AIG analyst commentary  »

Deutsche Bank closes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$13.31

-4.75 (-26.30%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Downgrade
Immunomedics rating change  »

Immunomedics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$4.92

0.015 (0.31%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Recommendations
GoPro analyst commentary  »

GoPro still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 25

    Feb

07:25
01/22/19
01/22
07:25
01/22/19
07:25
General news
FX Update »

FX Update: A generally…

SRNE

Sorrento Therapeutics

$2.30

0.04 (1.77%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Hot Stocks
Sorrento Therapeutics announces interim RTX study data »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

, SNY

Sanofi

$41.50

-0.54 (-1.28%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Recommendations
Lexicon, Sanofi analyst commentary  »

Lexicon price target…

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

SNY

Sanofi

$41.50

-0.54 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

FTNT

Fortinet

$70.50

-2.1 (-2.89%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Downgrade
Fortinet rating change  »

Fortinet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

  • 25

    Feb

ATI

Allegheny Technologies

$25.48

0.5 (2.00%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Earnings
Allegheny Technologies reports Q4 EPS 30c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IRMD

iRadimed

$25.77

0.32 (1.26%)

07:21
01/22/19
01/22
07:21
01/22/19
07:21
Hot Stocks
iRadimed suspends sales of 3880 patient vital signs monitoring system »

iRadimed announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AINV

Apollo Investment

$14.51

-0.01 (-0.07%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Upgrade
Apollo Investment rating change  »

Citi upgrades Apollo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

FITB

Fifth Third

$27.00

0.59 (2.23%)

, MBFI

MB Financial

$44.59

0.83 (1.90%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Hot Stocks
Fifth Third sees FY19 NII up approx. 3% from FY18 »

Sees Q1 NII down 1.5%-2%…

FITB

Fifth Third

$27.00

0.59 (2.23%)

MBFI

MB Financial

$44.59

0.83 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

ICE

IntercontinentalExchange

, CME

CME Group

$183.47

2.25 (1.24%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Recommendations
IntercontinentalExchange, CME Group analyst commentary  »

Citi upgrades ICE to Buy,…

ICE

IntercontinentalExchange

CME

CME Group

$183.47

2.25 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 08

    May

  • 28

    May

MO

Altria Group

$48.29

1.22 (2.59%)

, PM

Philip Morris

$73.77

1.25 (1.72%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Downgrade
Altria Group, Philip Morris rating change  »

Altria Group downgraded…

MO

Altria Group

$48.29

1.22 (2.59%)

PM

Philip Morris

$73.77

1.25 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 18

    Feb

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

, AGN

Allergan

$160.28

3.74 (2.39%)

07:16
01/22/19
01/22
07:16
01/22/19
07:16
Periodicals
Aurinia CEO says VOS could become blockbuster treatment, STATNews reports »

Though Aurinia…

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

AGN

Allergan

$160.28

3.74 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 18

    May

  • 28

    May

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Recommendations
Amazon.com analyst commentary  »

Amazon.com remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Hot Stocks
Crispr Therapeutics signs collaboration agreement with ProBioGen »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$164.13

3.78 (2.36%)

07:13
01/22/19
01/22
07:13
01/22/19
07:13
Initiation
Constellation Brands initiated  »

Constellation Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

HBM

Hudbay Minerals

$5.65

0.03 (0.53%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Hudbay Minerals rating change  »

Hudbay Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Crispr Therapeutics rating change  »

Citi downgrades Crispr…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

$1.92

-0.05 (-2.54%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

FB

Facebook

$150.01

1.77 (1.19%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Periodicals
VC says Facebook the most 'vulnerable' big tech firm, CNBC reports »

Facebook is the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Hot Stocks
Peoples Bancorp reports Q4 net interest margin 3.77% vs. 3.68% sequentially »

Compared to 3.63% for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

AXGN

AxoGen

$16.00

0.64 (4.17%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Hot Stocks
AxoGen appoints Eric Sandberg CCO »

AxoGen (AXGN) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Earnings
Peoples Bancorp reports Q4 EPS 71c, consensus 67c »

Earnings per diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CTSO

CytoSorbents

$7.66

0.04 (0.52%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Hot Stocks
CytoSorbents expands partnership with Fresenius Medical Care to Korea and Mexico »

CytoSorbents announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.